GLENMARK:NSE:NSE-Glenmark Pharmaceuticals Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1388

Change

+53.75 (+4.03)%

Market Cap

USD 373.94B

Volume

0.64M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

-1.15 (-0.02%)

USD 1,513.85B
CIPLA:NSE Cipla Limited

+17.95 (+1.28%)

USD 1,191.84B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+48.45 (+1.65%)

USD 1,023.22B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+6.25 (+0.56%)

USD 970.36B
MANKIND:NSE Mankind Pharma Ltd

+4.05 (+0.18%)

USD 960.38B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

+15.80 (+1.81%)

USD 890.87B
LUPIN:NSE Lupin Limited

+56.90 (+2.91%)

USD 868.96B
AUROPHARMA:NSE Aurobindo Pharma Limited

+41.25 (+3.92%)

USD 639.93B
ABBOTINDIA:NSE Abbott India Limited

-91.80 (-0.29%)

USD 633.57B
ALKEM:NSE Alkem Laboratories Limited

+81.85 (+1.77%)

USD 593.38B

ETFs Containing GLENMARK:NSE

SCIF 0.00 % 0.83 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.03% 64% D 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.03% 64% D 69% C-
Trailing 12 Months  
Capital Gain 49.83% 88% B+ 92% A
Dividend Return 0.27% 16% F 21% F
Total Return 50.10% 86% B+ 92% A
Trailing 5 Years  
Capital Gain 396.96% 73% C 73% C
Dividend Return 4.48% 48% F 28% F
Total Return 401.43% 73% C 72% C
Average Annual (5 Year Horizon)  
Capital Gain 39.18% 67% D+ 55% F
Dividend Return 39.69% 67% D+ 55% F
Total Return 0.50% 45% F 41% F
Risk Return Profile  
Volatility (Standard Deviation) 57.15% 37% F 42% F
Risk Adjusted Return 69.45% 65% D 53% F
Market Capitalization 373.94B 88% B+ 90% A-

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector